Piper Sandler Maintains Overweight on Fulcrum Therapeutics, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Fulcrum Therapeutics (NASDAQ:FULC) and increased the price target from $13 to $15.
February 28, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Fulcrum Therapeutics and raised the price target from $13 to $15.
The increase in price target by a reputable analyst firm like Piper Sandler typically signals a positive outlook on the company's future performance. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100